Marie-Claire Rickard, Governance and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager

Similar documents
M. Rickard, Research Governance and GCP Manager R. Fay Research Governance and GCP Manager Elizabeth Clough, Governance Operations Manager

M Rickard, Research Governance and GCP Manager Elizabeth Clough, R&D Governance Operations Manager Rachel Fay, Research Governance and GCP Manager

Marie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager

Informed Consent SOP Number: 25 Version Number: 6.0 Effective Date: 1 st September 2017 Review Date: 1 st September 2019

R. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager

Keele Clinical Trials Unit

Standard Operating Procedure (SOP) Research and Development Office

STANDARD OPERATING PROCEDURE

Standard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research

MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS

Gaining NHS Trust R&D Approvals

Standard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH. Chief and Principal Investigators of research sponsored and/or hosted by UHBristol

STANDARD OPERATING PROCEDURE

STANDARD OPERATING PROCEDURE

MHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager

STANDARD OPERATING PROCEDURE SOP 325

STANDARD OPERATING PROCEDURE SOP 715. Principles of Clinical Research Laboratory Practice

SOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School

STANDARD OPERATING PROCEDURE

Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs

Standard Operating Procedure (SOP) for Reporting Urgent Safety Measures in Clinical Research

Risk Assessment. Version Number 1.0 Effective Date: 21 st March Sponsored Research

Details: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure

Sponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law

Standard Operating Procedure (SOP)

Standard Operating Procedure (SOP) Research and Development Office

Standard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018

Standard Operating Procedure:

STANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager

Trial Management: Trial Master Files and Investigator Site Files

Research Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004

Risk Assessment and Monitoring

STANDARD OPERATING PROCEDURE

This Agreement dated DD/MM/YYYY (the Effective Date ) is between

Document Title: GCP Training for Research Staff. Document Number: SOP 005

SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup

Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026

Storage and Archiving of Research Documents SOP 6

Document Title: Research Database Application (ReDA) Document Number: 043

Corporate. Research Governance Policy. Document Control Summary

Quality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D

Research Staff Training

Document Title: Research Database Application (ReDA) Document Number: 043

Document Title: File Notes. Document Number: 024

ACTIONS/PSOP/001 Version 1.0 Page 2 of 6

Auditing of Clinical Trials

Study Monitoring Plan Template

STANDARD OPERATING PROCEDURE

STANDARD OPERATING PROCEDURE

Keele Clinical Trials Unit

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Document Title: Document Number:

MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC

SOP18b: Standard Operating Procedure for Preparing for External Audit and Inspection

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Standard Operating Procedure (SOP) Research and Development Office

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

TRAINING REQUIREMENTS FOR RESEARCH STAFF, INCLUDING GOOD CLINICAL PRACTICE (GCP)

Research & Development Quality Manual

Site Closedown Checklist for UoL Sponsored CTIMP Studies

Document Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator

STANDARD OPERATING PROCEDURE

Joint R&D Support Office SOP S-2011 UHL

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Document Title: Study Data SOP (CRFs and Source Data)

PREDNOS 2 Newsletter. randomised controlled trial (RCT).

Standard Operating Procedure

GCP INSPECTORATE GCP INSPECTIONS METRICS REPORT

STANDARD OPERATING PROCEDURE SOP 205

1. INTRODUCTION 2. SCOPE 3. PROCESS

Monitoring Clinical Trials

Reference Number: UHB 253 Version Number: 1 Date of Next Review: 22/01/2018 Previous Trust/LHB Reference Number: SR-RG-015

POLICY ON RESEARCH RELATED ADVERSE EVENT REPORTING

Standard Operating Procedure Research Governance

SOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY. Contact Jess Bisset, Research Operations Manager x20227

Governance %%.4- r2&% Queen s University Belfast. Standard Operating Procedure Research Governance. r2.aoc7. Research and Enterprise

20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice

Document Title: Investigator Site File. Document Number: 019

Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust

Research Adverse Event and Safety Reporting Procedures Outcome Statement: Title:

Joint Statement on the Application of Good Clinical Practice to Training for Researchers

Document Title: Informed Consent for Research Studies

Document Title: Version Control of Study Documents. Document Number: 023

ABMU R&D Operational Framework

Research & Development. Case Report Form SOP. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff

Version Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Once the feasibility assessment has been conducted the study team will be notified via (Appendix 3) of the outcome and whether the study is;

IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES

Preparation for an MHRA GCP Inspection including Training on New and Up-dated SOPs

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

STANDARD OPERATING PROCEDURE SOP 220. Investigation of allegations of Research Fraud and Misconduct. NNUH UEA Joint Research Office

Safety Reporting in Clinical Research Policy Final Version 4.0

Investigator Site File Standard Operating Procedure (SOP)

NHS REC Applications

Standard Operating Procedures

The changing regulatory and governance environment. for health research across the UK. a guide for researchers. November 2009 v.1

PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES

MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-D

STH Researcher. Recording of research information in patient case notes

Transcription:

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of or the Trial Protocol SOP Number: 037 Version Number: 5.0 Effective Date: 17/6/16 Review Date: 17/6/18 Author: Reviewer: Reviewer : Authorisation: Name / Position Signature Marie-Claire Rickard, Governance and Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager Sally Burtles, Director of Research Services & Business Development Date 1/6/16 Purpose and Objective: To identify and standardise the process for reporting Serious Breaches of or the trial protocol. Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 [Statutory Instrument 2004/1031], as amended by Statutory Instrument 2006/1928, contains a requirement for the notification of serious breaches of or the trial protocol, by the sponsor to the MHRA within 7 days of becoming aware of that breach. NHS REC committees also require serious breaches to be reported to the approving REC within 7 days. It is the responsibility of all staff involved in a study to identify and report potential serious breaches occurring during the day to day running of a clinical trial. The sponsor is responsible for assessing potential serious breaches, for the final decision of whether the event is consider to be a serious breach and for notifying the MHRA of any serious breach. Scope: This SOP applies to all studies sponsored or hosted by Bart s Health NHS Trust or Queen Mary University of London. The majority of instances of deviations or breaches are technical deviations that do not result in harm to the trial subjects or significantly affect the scientific value of the reported results of the trial. These cases should be documented e.g. in the Case Report Form (CRF) for the trial or Trial Master File (TMF) in order for appropriate corrective and preventative actions to be taken. In addition, these deviations should be included and considered when the clinical study report is produced as they may have an impact on the analysis of data. However, not every deviation from the protocol needs to be reported to the Joint Research Management Office (JRMO) as a serious breach. Abbreviations: BH Barts Health NHS Trust JRMO Joint Research Management Office QMUL Queen Mary University of London Definitions (if needed) Serious breach (As defined by MHRA): A serious breach of or the trial protocol is defined as a breach which is likely to affect to a significant degree: i) The safety or physical or mental integrity of the subjects of the trial or ii) The scientific value of the trial. Hosted Studies: Externally sponsored studies. Relevant SOPs SOP 31 Non-conformances SOP 37 Serious Breaches V5 Page 1 of 5

SOP Text Responsibility Activity 1. All Identify the existence of a potential breach or deviation from/of or the protocol during the day to day running of the trial and inform the PI. 2. Principal Responsibility 3. RG and A serious breach of or the trial protocol is defined as a breach which is likely to affect to a significant degree: i) The safety or physical or mental integrity of the subjects of the trial or ii) The scientific value of the trial In addition all breaches of : (a) The conditions and principles of in connection with that trial; or (b) The protocol relating to that trial, (including all amendments) should be reported. Notify the sponsor immediately. (If the study is sponsored by BH or QM, the contact point is the JRMO Research Governance and for the study). Initial notification can be made via telephone or email. As much information as possible should be provided. (The 7 day notification to MHRA clock commences here). The initial notification should be followed by written notification of a potential serious breach. The PI should send the notification form to the sponsor representative within 24hrs of becoming aware of the potential breach. If the incident involves a BH Trust patient or staff member, consider if it meets the requirements of the Trust Incident Reporting policy as necessary. For CTIMP Studies For BH and QM sponsored studies Activity Review the incident/event. When notified of a potential serious breach, the information should be reviewed in a timely manner. Any additional information required should be requested. Inform the QA Manager about the incident/event 4. QA Manager Log the incident/event appropriately in the study file and central log. Once informed by the RG and, the QA Manager should log the initial report and make sure the event is followed to resolution. 5. RG and Assess the incident/event and decide if it is a serious breach. Once necessary information has been received, the RG & manager should decide if the incident or event is a serious breach. Please refer to the MHRA website for further guidance on the notification of serious breaches of or the trial protocol. If the incident/event meets the criteria of a serious breach, the MHRA Notification of Potential Serious Breach of or Trial Protocol Form (see Associated Document 1) should be completed. If the incident/event is deemed not to be a potential serious breach, the PI and research team may still need guidance and it should still be followed-up to ensure it is managed appropriately. In most cases the CI/PI and research team will be in agreement on whether a breach exists. If there is disagreement on the issue, it should be discussed but the sponsor is ultimately responsible for making this decision. Evidence and reasons behind the decision made should be carefully documented and filed appropriately. NB: The safety or physical or mental integrity of the subjects of the trial should be relevant to trial subjects in the UK. The MHRA guidance indicates that all other aspects should be reported for even if for non UK sites. SOP 37 Serious Breaches V5 Page 2 of 5

6. RG and Submit completed Notification of Potential Serious Breach of or Trial Protocol Form (Associated Document 1) to MHRA within 7 days. Details about how to submit to the MHRA can be found on the MHRA website. Ensure agreed corrective and preventative actions are included. Ensure both the study team and JRMO files receive a copy of the document sent to the MHRA. The MHRA will confirm receipt of the potential breach and an inspector will be allocated to the breach for review. 7. Inform the REC about the serious breach within 7 days. REC submission takes the form of a copy of the MHRA submission plus cover letter. This can be emailed or posted to the REC which approved the study. Ensure any/all follow-up information is forwarded on. 8. RG and Manager/ Principal 9. Sponsor representative or PI 10. RG and Manager/ Team 11. RG and Manager/QA Manager Provide relevant information and follow up to the MHRA. The Research Governance and and PI should work together to provide relevant information to the MHRA and follow up any further actions the MHRA request. The Research Governance and and PI must ensure all required actions are completed and that the breach is then closed. The MHRA will formally email to state no further information is required. For hosted CTIMP studies Inform JRMO of potential breach and forward all relevant paperwork. Review serious breach and record with study documentation. As it is the sponsor s responsibility to assess the breach and ensure resolution, the JRMO Research Governance & will assist only where requested or where necessary. For Non CTIMP Studies For BH and QM sponsored studies Review the incident/event. When notified of a potential serious breach, the information should be reviewed in a timely manner. Any additional information required should be requested. 12. QA Manager Log the incident/event appropriately in the study file and central log. Once informed by the RG and, the QA Manager should log the initial report and make sure the event is followed to resolution. 13. RG and 14. Principal 15. Principal / RG and Asses the incident/event and decide if it is a serious breach. If the incident/event meets the criteria of a serious breach, the Notification of Potential Serious Breach of or Trial Protocol Form (Associated Document 2) should be completed. If the incident/event is deemed not to be a potential serious breach, the CI/PI and research team may still need guidance and it should still be followed-up to ensure it is managed appropriately. NB: In most cases the CI/PI and research team will be in agreement on whether a breach exists. If there is disagreement on the issue, it should be discussed but the sponsor is ultimately responsible for making this decision. Evidence and reasons behind the decision made should be carefully documented and filed appropriately. Submit to the approving REC for the attention of the Chairperson. Document and describe the event, including both corrective and preventative action taken or planned, including supporting documentation as needed. Ensure all required actions are completed. The PI, with the support of the RG and, must ensure all required actions are completed and that the breach is then closed. The REC will acknowledge in writing and further information or clarification may be requested until the incident is closed. SOP 37 Serious Breaches V5 Page 3 of 5

16. Sponsor representative or PI 17. RG and Manager/ Team For hosted Non-CTIMP studies Inform JRMO of potential breach and forward all relevant paperwork. Review serious breach and record with study documentation. As it is the sponsor s responsibility to assess and ensure resolution, the JRMO RG & will assist only when requested or when necessary. Change Control This section outlines changed from version 4.0 to version 5.0 Section Changed Summary and description of change All New template used All Minor corrections Relevant SOPs Relevant SOPs added 4 QA Manager responsibilities added Associated Documents Addition of Non- CTIMP form List of Associated Documents (these are standalone documents) Associated Document 1 Associated Document 2 Document name MHRA Notification of Serious Breach of or Trial Protocol Form Non-CTIMP - Notification of Serious Breach of or Trial Protocol Form SOP 37 Serious Breaches V5 Page 4 of 5

FLOW CHART Research team identifies an incident/event Principal notifies the sponsor immediately manager to review and assess the incident/event and decide if it is a serious breach. Serious breach Non Serious breach manager to followed-up to ensure it is managed appropriately. CTIMP Non-CTIMP to submit completed Notification of Potential Serious Breach of or Trial Protocol Form to MHRA within 7 days. Principal to inform the REC about the serious breach within 7 days SOP 37 Serious Breaches V5 Page 5 of 5